Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11164
Title: Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy.
Authors: Hamilton, E J;Gianatti, Emily J;Strauss, B J;Wentworth, J;Lim-Joon, D;Bolton, Damien M;Zajac, J D;Grossmann, Mathis
Affiliation: Department of Medicine, Austin Health/Northern Health, University of Melbourne, Heidelberg, Vic., Australia.
Issue Date: 1-Mar-2011
Citation: Clinical Endocrinology; 74(3): 377-83
Abstract: Androgen deprivation therapy (ADT) for prostate cancer is associated with increases in fat mass and risk of type 2 diabetes; however, the relationship between sex steroid deficiency and abdominal fat distribution remains controversial.We conducted a 12-month prospective observational study at a tertiary referral centre.We investigated changes in abdominal fat distribution and insulin resistance in 26 men (70.6±6.8 years) with nonmetastatic prostate cancer during the first year of ADT.Twelve months of ADT increased visceral abdominal fat area by 22% (from 160.8±61.7 to 195.9±69.7 cm(2) ; P<0.01) and subcutaneous abdominal fat area by 13% (from 240.7±107.5 to 271.3±92.8 cm(2) ; P<0.01). Fat mass increased by 14% (+3.4 kg; P<0.001) and lean tissue mass decreased by 3.6% (-1·9 kg; P<0.001). Insulin resistance (HOMA-IR) increased by 12% (2.50±1.12 to 2.79±1.31, P<0.05). There was no change in fasting glucose or glycated haemoglobin levels. Total testosterone (TT) was inversely associated with visceral fat area independent of oestradiol (E2), but E2 was not associated with visceral fat area independent of TT. Visceral fat area, not TT or E2, was independently associated with insulin resistance.ADT for prostate cancer results in accumulation of both visceral and subcutaneous abdominal fat. Increased visceral fat area appears more closely linked to testosterone than oestradiol deficiency. Increased insulin resistance may arise secondary to visceral fat accumulation, rather than as a direct result of sex steroid deficiency.
Internal ID Number: 21118287
URI: http://ahro.austin.org.au/austinjspui/handle/1/11164
DOI: 10.1111/j.1365-2265.2010.03942.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/21118287
Type: Journal Article
Subjects: Analysis of Variance
Androgen Antagonists.adverse effects.therapeutic use
Estradiol.blood
Humans
Immunoassay.methods
Insulin Resistance
Intra-Abdominal Fat.drug effects.metabolism
Linear Models
Male
Prospective Studies
Prostatic Neoplasms.blood.drug therapy.metabolism
Risk Assessment
Risk Factors
Subcutaneous Fat, Abdominal.drug effects.metabolism
Testosterone.blood
Time Factors
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.